What is Regenxbio's G&A?

Regenxbio (RGNX) reported G&A of $21.31M in Q1 2026.

How has Regenxbio's G&A changed year-over-year?

Regenxbio's G&A increased by 4.7% year-over-year, from $20.35M to $21.31M.

What is the long-term trend for Regenxbio's G&A?

Over 4 years (2021 to 2025), Regenxbio's G&A has grown at a 1.1% compound annual growth rate (CAGR), from $79.33M to $82.86M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Regenxbio RGNX G&A

G&A at other companies

EyePoint, Inc. EYPT

$15.24M+9.9%

4D Molecular TherapeuticsFDMT

$11.69M-9.7%

Solid Biosciences Inc.SLDB

$11.17M+22.2%

Immix Biopharma, Inc.IMMX

$4.82M+78.1%

XencorXNCR

$17.71M+2.1%

Sutro BiopharmaSTRO

$7.58M-42.9%

Other financials

Income statement

See full

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

See full

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

See full

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

See full

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

See full

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

See full

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regenxbio's G&A?: Regenxbio (RGNX) reported G&A of $21.31M in Q1 2026.
How has Regenxbio's G&A changed year-over-year?: Regenxbio's G&A increased by 4.7% year-over-year, from $20.35M to $21.31M.
What is the long-term trend for Regenxbio's G&A?: Over 4 years (2021 to 2025), Regenxbio's G&A has grown at a 1.1% compound annual growth rate (CAGR), from $79.33M to $82.86M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.